Search
Collegium Pharmaceutical Inc
COLLAdd to Watchlist
36.738USD
+0.868+2.42%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.19BMarket Cap
15.58P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.42%
5 Days
+3.25%
1 Month
+15.60%
6 Months
-20.65%
Year to Date
-20.65%
1 Year
+21.25%
Key Figures
36.470Open
37.150High
295.89KVolume
15.58P/E TTM
4.04P/E Dynamic
--Dividend TTM
0.91%Turnover Ratio
35.870Prev. Close
36.000Low
8.89MTurnover
17.21P/E Static
3.81P/B
0.00%Div Yield TTM
4.57%ROA
50.78752wk High
0.90Volume Ratio
69.19MNet Profit
32.41MShares
2.3586EPS TTM
0.75Beta
27.41%ROE
28.73552wk Low
3.21%Amplitude
60.59%Gross Margin
1.19BMarket Cap
8.10Reward/Risk
2.18%Risk Rate
TradingKey Stock Score of Collegium Pharmaceutical Inc
Currency: USD Updated: 2026-07-01Key Insights
Collegium Pharmaceutical Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Collegium Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Collegium Pharmaceutical Inc Highlights
StrengthsRisks
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.72% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 780.57M.
Fairly Valued
The company’s latest PE is 15.21, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 38.69M shares, decreasing 9.82% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 103.03K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
54.333
Target Price
+50.09%
Upside Space
Collegium Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Collegium Pharmaceutical Inc Info
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Ticker SymbolCOLL
CompanyCollegium Pharmaceutical Inc
CEOKarnani (Vikram)
Websitehttps://www.collegiumpharma.com/
Related Instruments
+1.33%
+2.83%
+5.32%
+3.44%
+2.26%
+3.06%
+3.01%
+2.95%
+3.47%
+1.82%
+4.20%
+1.56%
+3.97%
+3.16%
+2.05%
0.00%
+3.30%
+3.10%
+0.25%
+4.50%Popular Instruments
52705.900
+451.600 (+0.86%)
29205.600
-593.700 (-1.99%)
7457.100
-18.400 (-0.25%)
14756.000
-599.000 (-3.90%)
67774.000
-1711.000 (-2.46%)
6341.100
+65.700 (+1.05%)
68.344
+0.376 (+0.55%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4112.580
+81.810 (+2.03%)
FAQs
What is the current price of Collegium Pharmaceutical Inc (COLL)?
The current price of Collegium Pharmaceutical Inc (COLL) is 35.87.
What is the symbol of Collegium Pharmaceutical Inc?
The ticker symbol of Collegium Pharmaceutical Inc is COLL.
What is the 52-week high of Collegium Pharmaceutical Inc?
The 52-week high of Collegium Pharmaceutical Inc is 50.79.
What is the 52-week low of Collegium Pharmaceutical Inc?
The 52-week low of Collegium Pharmaceutical Inc is 28.73.
What is the market capitalization of Collegium Pharmaceutical Inc?
The market capitalization of Collegium Pharmaceutical Inc is 1.16B.
Is Collegium Pharmaceutical Inc (COLL) currently rated as Buy, Hold, or Sell?
According to analysts, Collegium Pharmaceutical Inc (COLL) has an overall rating of Buy, with a price target of 54.33.
What is the Earnings Per Share (EPS TTM) of Collegium Pharmaceutical Inc (COLL)?
The Earnings Per Share (EPS TTM) of Collegium Pharmaceutical Inc (COLL) is 1.98.